keyword
MENU ▼
Read by QxMD icon Read
search

immunotherapy allergen

keyword
https://www.readbyqxmd.com/read/28219072/human-allergen-specific-igg-subclass-antibodies-measured-using-immunocap-technology
#1
Robert Movérare, Karin Blume, Peter Lind, René Crevel, Åsa Marknell DeWitt, Stella Cochrane
BACKGROUND: Knowledge of human IgG subclass antibody responses to various allergens has been hampered by a lack of reliable standardized assays. The aim here was to develop quantitative immunoassays for human IgG1, IgG2, and IgG3 antibodies using ImmunoCAP® technology and to evaluate their application. METHODS: Enzyme conjugates with isotype-specific monoclonal antibodies and calibrators composed of purified myeloma paraproteins were developed for each assay and used together with other standardized assay reagents for the Phadia® 100 instrument...
February 21, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28219062/the-impact-on-allergy-related-cells-of-a-birch-pollen-allergoid-with-and-without-monophosphoryl-lipid-a-in-comparison-with-the-native-equivalent
#2
Margitta Worm, Dennis Ernst, Markus Kraller, Magda Babina
BACKGROUND: The clinical efficacy and safety of allergoid immunotherapy have been demonstrated in clinical trials. However, simultaneous monitoring of the immunological changes by allergoids versus allergens in the cells of the same individual has not been extensively performed, and the impact of concurrent Toll-like receptor 4 (TLR4) ligation has not been specified. METHODS: Three types of birch allergen were utilized: glutaraldehyde-treated allergoid (extract A), the same allergoid plus monophosphoryl lipid A (MPL), i...
February 21, 2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28212503/lactobacillus-buchneri-s-layer-as-carrier-for-an-ara-h-2-derived-peptide-for-peanut-allergen-specific-immunotherapy
#3
Julia Anzengruber, Merima Bublin, Eva Bönisch, Bettina Janesch, Angelika Tscheppe, Matthias L Braun, Eva-Maria Varga, Christine Hafner, Heimo Breiteneder, Christina Schäffer
Peanut allergy is an IgE-mediated severe hypersensitivity disorder. The lack of a treatment of this potentially fatal allergy has led to intensive research on vaccine development. Here, we describe the design and initial characterization of a carrier-bound peptide derived from the most potent peanut allergen, Ara h 2, as a candidate vaccine. Based on the adjuvant capability of bacterial surface (S-) layers, a fusion protein of the S-layer protein SlpB from Lactobacillus buchneri CD034 and the Ara h 2-derived peptide AH3a42 was produced...
February 14, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/28211342/key-issues-in-hymenoptera-venom-allergy-an-update
#4
REVIEW
T Alfaya Arias, V Soriano Gómis, T Soto Mera, A Vega Castro, J M Vega Gutiérrez, A Alonso Llamazares, D Antolín Amérigo, F J Carballada Gonzalez, C Dominguez Noche, D Gutierrez Fernandez, L Marques Amat, A Martinez Arcediano, M Martinez San Ireneo, A Moreno Ancillo, Y Puente Crespo, B Ruiz Leon, L Sánchez Morillas
In this review, the Hymenoptera Allergy Committee of the SEAIC analyzes the most recent scientific literature addressing problems related to the diagnosis of hymenoptera allergy and to management of venom immunotherapy. Molecular diagnosis and molecular risk profiles are the key areas addressed. The appearance of new species of hymenoptera that are potentially allergenic in Spain and the associated diagnostic and therapeutic problems are also described. Finally, we analyze the issue of mast cell activation syndrome closely related to hymenoptera allergy, which has become a new diagnostic challenge for allergists given its high prevalence in patients with venom anaphylaxis...
2017: Journal of Investigational Allergology & Clinical Immunology
https://www.readbyqxmd.com/read/28197701/-innovative-forms-of-specific-immunotherapy
#5
REVIEW
P Zieglmayer
The clinical efficacy of allergen-specific immunotherapy depends on tolerance induction. Treatment success is currently limited by treatment-related adverse reactions. Novel approaches mainly target improvement of tolerability in addition to optimized immunogenicity. For epicutaneous immunotherapy (EPIT), commercially available treatment extracts are applied to skin via a patch. The route exhibits excellent tolerability and good clinical efficacy. The first encouraging data on a peanut EPIT were published in 2016...
February 14, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28196255/effect-of-2-years-of-treatment-with-sublingual-grass-pollen-immunotherapy-on-nasal-response-to-allergen-challenge-at-3-years-among-patients-with-moderate-to-severe-seasonal-allergic-rhinitis-the-grass-randomized-clinical-trial
#6
Guy W Scadding, Moises A Calderon, Mohamed H Shamji, Aarif O Eifan, Martin Penagos, Florentina Dumitru, Michelle L Sever, Henry T Bahnson, Kaitie Lawson, Kristina M Harris, Audrey G Plough, Joy Laurienzo Panza, Tielin Qin, Noha Lim, Nadia K Tchao, Alkis Togias, Stephen R Durham
Importance: Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal allergic rhinitis. Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy has been shown to improve symptoms for at least 2 years following discontinuation of treatment. Objective: To assess whether 2 years of treatment with grass pollen sublingual immunotherapy, compared with placebo, provides improved nasal response to allergen challenge at 3-year follow-up...
February 14, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28194483/-placebo-effect-in-clinical-trials-with-allergen-specific-immunotherapy-with-inhalant-allergens
#7
B Wedi, D Wieczorek, A Kapp
Placebo effects play an important role in the treatment of allergic diseases. Therefore, in this study, we analysed the described effects of placebo in all double-blind placebo-controlled clinical trials of allergen-specific immunotherapy (ASIT) with inhalant allergens (birch, grass, house dust mites) listed in the tables (updated July 2016) attached to the German S2k guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. The most common placebo consisted of verum without allergen, but when the subcutaneous route was used, histamine was sometimes added...
February 13, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28193791/epinephrine-for-first-aid-management-of-anaphylaxis
#8
Scott H Sicherer, F Estelle R Simons
Anaphylaxis is a severe, generalized allergic or hypersensitivity reaction that is rapid in onset and may cause death. Epinephrine (adrenaline) can be life-saving when administered as rapidly as possible once anaphylaxis is recognized. This clinical report from the American Academy of Pediatrics is an update of the 2007 clinical report on this topic. It provides information to help clinicians identify patients at risk of anaphylaxis and new information about epinephrine and epinephrine autoinjectors (EAs). The report also highlights the importance of patient and family education about the recognition and management of anaphylaxis in the community...
February 13, 2017: Pediatrics
https://www.readbyqxmd.com/read/28188713/-safety-of-subcutaneous-immunotherapy-with-tyrosine-adsorbed-house-dust-mite-extracts-in-patients-with-allergic-disease
#9
Mónica María Molina-Sáenz, Ana María Villa-Arango, Ricardo Cardona-Villa
BACKGROUND: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions. OBJECTIVE: To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts. METHODS: Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system...
January 2017: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/28188710/-prevalence-of-sensitization-to-inhalant-allergens-in-the-immunology-department-from-hospital-de-especialidades-pedi%C3%A3-tricas-mar%C3%A3-a-honduras-2016
#10
Victoria Alejandra Gonzales-González, Adolfo Martín Díaz-Flores, Karla Zobeyda Fernández-Zelaya, María Félix Rivera-Reyes
BACKGROUND: Allergic diseases are a public health problem; estimates indicate that between 30% and 40% of the world population is affected by some allergy. Knowing the prevalence of allergen sensitization allows for adequate diagnoses and treatments to be offered. In Honduras there are no studies available in pediatric patients. OBJECTIVE: The purpose of this research was to identify the most common types of sensitization in children and their correlation with the most common allergic diseases in patients on immunotherapy at the Maria Hospital of Pediatric Specialties...
January 2017: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/28181151/update-on-potential-therapies-for-ige-mediated-food-allergy
#11
REVIEW
Andrew MacGinnite
PURPOSE OF REVIEW: Food allergy is common, affecting up to 8% of children in the USA. Currently, therapy is limited to avoidance of the implicated allergen and availability of self-injectable epinephrine. However, several new approaches to food allergy are under investigation. This article reviews the published data on these new approaches. RECENT FINDINGS: Oral immunotherapy, in which allergic subjects are exposed to increasing amounts of antigen, can be accomplished in the majority of allergic individuals...
January 2017: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/28164402/allergen-specific-immunotherapy-prescription-patterns-in-veterinary-practice-a-us-population-based-cohort-study
#12
Kathy Chu Tater, William Elliott Cole, Paul David Pion
BACKGROUND: Poor adherence to continuing allergen-specific immunotherapy treatment (ASIT) may be an issue in veterinary medicine. No studies describe how allergen tests are used in general veterinary practice, including the percentage of patients that receive ASIT after allergen testing. HYPOTHESIS/OBJECTIVES: Assess veterinary ASIT patterns in United States general practices. ANIMALS: Dogs (n = 2,557) and 121 cats allergen-tested at 177 hospitals (173 general practice and four specialty practices) in 44 states...
February 5, 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28162007/clinical-use-of-adjuvants-in-allergen-immunotherapy
#13
L Klimek, C B Schmidt-Weber, M F Kramer, M A Skinner, M D Heath
Introduction Allergen-specific Immunotherapy (AIT) is the only available treatment aimed to tackle the underlying causes of allergy. The active components of subcutaneous vaccines traditionally consist of natural or modified allergen extracts which can be combined with adjuvant platforms. In recent years new targets have been further developed in an attempt to raise the safety and efficacy profile of AIT. Areas Covered In this review, we discuss the desirable attributes of adjuvants and delivery systems from empiricism to rational design, for current and future clinical applications in AIT...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28160513/the-clinical-and-immunological-effects-of-pru-p-3-slit-on-peach-and-peanut-allergy-in-patients-with-systemic-reactions
#14
F Gomez, G Bogas, M Gonzalez, P Campo, M Salas, A Diaz-Perales, M J Rodriguez, A Prieto, D Barber, M Blanca, M J Torres, C Mayorga
BACKGROUND: The peach non-specific lipid transfer protein (nsLTP), Pru p 3, is the primary sensitizer in fruits and responsible for severe reactions in the Mediterranean area. Peach allergy is frequently associated with other allergies such as peanut. Therefore, it is important to assess how specific immunotherapy to Pru p 3 could affect both peach and peanut tolerance. OBJECTIVES: To evaluate peach and peanut desensitization and immunological changes after one year of Pru p 3 sublingual immunotherapy (SLIT) in patients with systemic allergic reactions to peach and/or peanut...
February 4, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28152347/allergen-immunotherapy-for-respiratory-allergic-disease-in-australia-in-2016
#15
William B Smith, Frank E Kette
No abstract text is available yet for this article.
February 6, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28152201/biomarkers-for-monitoring-clinical-efficacy-of-allergen-immunotherapy-for-allergic-rhinoconjunctivitis-and-allergic-asthma-an-eaaci-position-paper
#16
M H Shamji, J H Kappen, M Akdis, E Jensen-Jarolim, E F Knol, J Kleine-Tebbe, B Bohle, A M Chaker, S J Till, R Valenta, L K Poulsen, M A Calderon, P Demoly, O Pfaar, L Jacobsen, S R Durham, C B Schmidt-Weber
Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma (1-12). AIT has disease modifying properties and confers long-term clinical benefit after cessation of treatment (6, 7, 13-17). AIT is routinely used in daily practice and can be administered either subcutaneously (SCIT) or sublingually (SLIT) (3-12). Although AIT is effective, the degree of remission strongly varies depending on the complex interaction between patient, allergy, symptomatology and vaccines used for AIT (3-9)...
February 2, 2017: Allergy
https://www.readbyqxmd.com/read/28151587/nonadherence-to-sublingual-immunotherapy-in-allergic-rhinitis-a-real-life-analysis
#17
Ting Wang, Yue Li, Feng Wang, Chengyong Zhou
BACKGROUND: To sustain the long-lasting beneficial effects of allergen-specific sublingual immunotherapy (SLIT), an adequate duration of treatment is required. Nevertheless, many patients discontinue prematurely and therefore fail to obtain satisfactory therapeutic effect in clinical practice. The aim of this study was to analyze the causes leading to premature discontinuation of SLIT in allergic rhinitis (AR), and to provide the corresponding countermeasures for the following SLIT course...
February 2, 2017: International Forum of Allergy & Rhinology
https://www.readbyqxmd.com/read/28141955/investigational-new-drugs-for-allergic-rhinitis
#18
Peter A Ricketti, Sultan Alandijani, Chen Hsing Lin, Thomas B Casale
Allergic rhinitis (AR) is a multifactorial disease characterized by paroxysmal symptoms of sneezing, rhinorrhea, postnasal drip and nasal congestion. For over a century, subcutaneous allergen immunotherapy (SCIT) has been recognized as the most effective therapy to date that may modify the underlying disease course and provide long-term benefits for individuals refractory to pharmacotherapy. However, over the past 25 years, there has been substantial growth in developing alternative therapies to traditional SCIT...
January 31, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28133873/the-future-of-immunotherapy-for-canine-atopic-dermatitis-a-review
#19
REVIEW
Douglas J DeBoer
Allergen specific immunotherapy (ASIT) is a foundation treatment for canine atopic dermatitis (CAD), though few critical studies have documented its effectiveness as a disease-modifying treatment in dogs. The mechanisms by which ASIT works in dogs have not been elucidated, although they are likely to parallel those known for humans. Current ASIT approaches in CAD focus on either subcutaneous or sublingual administration. Greater knowledge of major allergens in dogs, ideal dosage regimes and details of allergen admixture are likely to lead to better efficacy in CAD...
February 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28132800/preparation-and-analysis-of-peanut-flour-used-in-oral-immunotherapy-clinical-trials
#20
Jelena P Berglund, Nicole Szczepanski, Anusha Penumarti, Ayeshia Beavers, Janelle Kesselring, Kelly Orgel, Bruce Burnett, A Wesley Burks, Michael Kulis
BACKGROUND: Oral immunotherapy (OIT) is an investigational therapeutic approach for the treatment of food allergies. Characterization of the drug product used in oral immunotherapy trials for peanut allergy has not been reported. OBJECTIVE: To quantify relative amounts of the major peanut allergens and microbial load present in peanut flour used in OIT trials and assess whether these parameters change over a 12-month period. We also anticipate that this report will serve as a guide for investigators seeking to conduct OIT trials under Food and Drug Administration-approved Investigational New Drug applications...
January 26, 2017: Journal of Allergy and Clinical Immunology in Practice
keyword
keyword
35131
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"